EyePoint Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate in fireside chats at the following upcoming investor conferences:
Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 1:25 p.m. ET
Goldman Sachs 46th Annual Global Healthcare ConferenceDate: Tuesday, June 10, 2025Time: 2:40 p.m. ET
Guggenheim BioFrontier Boston EventDate: Wednesday, June 25, 2025Time: 4:00 p.m. ET
A live webcast and subsequent archived replay of each fireside chat may be accessed via the Investors section of the Company website at www.eyepointpharma.com.
About EyePoint
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company's lead product candidate, DURAVYU™ is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. Supported by robust safety and efficacy data to date, DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration, the leading cause of vision loss among people 50 years of age and older in the United States and recently completed a Phase 2 clinical trial in diabetic macular edema.
The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products in multiple disease indications. EyePoint is headquartered in Watertown, Massachusetts, and operates a commercial-scale manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product candidate; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Tanner Kaufman / Jenni LuFTI Consulting Direct: 203-722-8743 / 667-321-6018tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com
Media Contact:
Amy PhillipsGreen Room CommunicationsDirect: 412-327-9499aphillips@greenroompr.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
‘Keep an Eye on the Bigger Picture,' Says Morgan Stanley About Tesla Stock
Tesla (NASDAQ:TSLA) stock took a sharp hit last week after Elon Musk and Donald Trump – once close buddies – turned on each other in a public social media spat that quickly became an online spectacle. While the internet grabbed its popcorn to watch the drama/comedy unfold, investors were less amused, driving the stock down and wiping out a record $152 billion in market value. Confident Investing Starts Here: Trump warned he might yank Elon's federal subsidies and contracts, while Musk took jabs at Trump's links to Jeffrey Epstein and called for his impeachment. Now, Trump says he's considering ditching his Tesla. But what does Wall Street have to say about all this madness? Morgan Stanley analyst Adam Jonas, one of the Street's biggest TSLA bulls, shared a 'few 'pith and marrow' thoughts' in the wake of the public spat. According to Trump, the whole thing kicked off because Musk was upset his 'Big Beautiful Bill' was not beneficial to Tesla. However, Jonas makes short shrift of the implications. 'We do not believe the phasing out of EV tax credits from the BBB (Big Beautiful Bill) is material to the long term outlook for TSLA,' the analyst said While Musk's involvement with the Trump administration and his increasingly polarizing politics were the cue from a massive drop in sales for Tesla earlier this year, Jonas does not think the argument will help bring back buyers that once considered buying a Tesla but were turned off by Musk's recent activities. In fact, Jonas thinks the argument could 'potentially (temporarily) alienate multiple sides of the political spectrum.' Yet, zooming out, Jonas thinks it's important to keep an eye on the bigger picture and that offers plenty of promise. 'While emotions are running high, we are not convinced the longer-term vectors that drive the stock's value have changed here,' he said. ' AI leadership, autonomy/robotics, manufacturing, supply chain re-architecture, renewable power, critical infrastructure… Tesla still holds so many valuable cards that are largely apolitical, in our opinion.' Nevertheless, investors should prepare for a rocky ride over the near-term. Donning his 'trading cap,' Jonas feels more confident about short-term volatility than about the stock's immediate direction. The analyst says he's sticking with his $410 price target on Tesla shares, even as he braces for the stock to post further losses. That figure implies a one-year gain of 36%. Meanwhile, Jonas maintains an Overweight rating (i.e., Buy). (To watch Jonas' track record, click here) That view, however, stands in contrast to the broader Street sentiment. Based on a mix of 16 Buys, 10 Holds, and 10 Sells, the analyst consensus rates the stock a Hold (i.e., Neutral). Going by the $285.91 average target, the shares are expected stay range-bound for the foreseeable future. (See TSLA stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Business Insider
an hour ago
- Business Insider
Lululemon Athletica (LULU) Gets a Hold from Barclays
Barclays analyst Adrienne Yih maintained a Hold rating on Lululemon Athletica (LULU – Research Report) on June 6 and set a price target of $270.00. The company's shares closed last Friday at $265.27. Confident Investing Starts Here: Yih covers the Consumer Cyclical sector, focusing on stocks such as American Eagle, Dick's Sporting Goods, and VF. According to TipRanks, Yih has an average return of 6.4% and a 49.70% success rate on recommended stocks. In addition to Barclays, Lululemon Athletica also received a Hold from Morgan Stanley's Alexandra Straton in a report issued yesterday. However, on June 6, KeyBanc reiterated a Buy rating on Lululemon Athletica (NASDAQ: LULU). Based on Lululemon Athletica's latest earnings release for the quarter ending February 2, the company reported a quarterly revenue of $3.61 billion and a net profit of $748.4 million. In comparison, last year the company earned a revenue of $3.21 billion and had a net profit of $669.47 million
Business Upturn
an hour ago
- Business Upturn
Ericsson bags multi-year NOC Managed Services contract with Bharti Airtel
Ericsson (NASDAQ: ERIC) has been awarded a significant multi-year Network Operations Center (NOC) Managed Services contract by Bharti Airtel, reinforcing the strong and enduring partnership between the two telecom giants. This strategic collaboration highlights Ericsson's leadership in managed services and its commitment to delivering superior network performance and value to Airtel's customers. Under this new agreement, Ericsson will deploy its advanced intent-based operations through a centralized NOC to efficiently manage Bharti Airtel's diverse network services. These include 4G, 5G Non-Standalone (NSA), 5G Standalone (SA), Fixed Wireless Access (FWA), Private Networks, and Network Slicing. The move aims to enhance network reliability, scalability, and innovation across Airtel's pan-India footprint. Ericsson's state-of-the-art NOC will play a crucial role in managing and scaling Airtel's expansive network infrastructure, especially focusing on expanding Fixed Wireless Access and Network Slicing capabilities throughout the country. This will empower Airtel to offer improved connectivity solutions and cater to evolving customer demands in the 5G era. Randeep Sekhon, CTO of Bharti Airtel, stated, 'We are excited to enhance our strong collaboration with Ericsson as we pursue our goal of creating a future-ready network that delivers an exceptional experience for our customers. We believe that these innovative technologies will empower us to meet the growing data demands of consumers in a digitally connected India.' With a partnership spanning over 25 years, Ericsson and Bharti Airtel have collaborated across multiple generations of mobile communication technologies. This latest contract follows Airtel's recent collaboration with Ericsson on 5G Core technology, further driving the evolution of India's 5G ecosystem. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
